Used to classify article posts by terms used for medical conditions. It’s mostly aimed at practitioners and physicians.

Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.

Authors: Mateus M Bergamaschi, Regina Helena Costa Queiroz, Marcos Hortes Nisihara Chagas, Danielle Chaves Gomes de Oliveira, Bruno Spinosa De Martinis, Flávio Kapczinski, João Quevedo, et al.
Neuropsychopharmacology, May 2011

Generalized Social Anxiety Disorder (SAD) is one of the most common anxiety conditions with impairment in social life. Cannabidiol (CBD), one major non-psychotomimetic compound of the cannabis sativa plant, has shown anxiolytic effects both in humans and in animals. This preli…

Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas–possible role of Cannabis inhalation.

Authors: Mansoor Foroughi, Glenda Hendson, Michael A. Sargent, Paul Steinbok
Child’s Nervous System, DATE

INTRODUCTION: Spontaneous regression of pilocytic astrocytoma after incomplete resection is well recognized, especially for cerebellar and optic pathway tumors, and tumors associated with Neurofibromatosis type-1 (NF1). The purpose of this report is to document spontaneous reg…

Cannabinoid hyperemesis: a case series.

Authors: Michael W. Donnino, Michael N. Cocchi, Joseph Miller, Jonathan Fisher
The Journal of Emergency Medicine, April 2011

BACKGROUND: Cannabinoid use is prevalent in the United States, with recent reports of increased usage among younger Americans. Traditionally, cannabinoids have been used recreationally or as antiemetics; however, recent reports suggest that chronic abuse can result in the para…

Role of cannabinoids in multiple sclerosis.

Authors: John P. Zajicek, Vicentiu I. Apostu
CNS Drugs, March 2011

Although extracts from the cannabis plant have been used medicinally for thousands of years, it is only within the last 2 decades that our understanding of cannabinoid physiology and the provision of evidence for therapeutic benefit of cannabinoids has begun to accumulate. Thi…

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease.

Authors: Cristina Blázquez, Anna Chiarlone, Onintza Sagredo, Tania Aguado, M. Ruth Pazos, et al
Brain, January 2011

Endocannabinoids act as neuromodulatory and neuroprotective cues by engaging type 1 cannabinoid receptors. These receptors are highly abundant in the basal ganglia and play a pivotal role in the control of motor behaviour. An early downregulation of type 1 cannabinoid receptor…

A combined preclinical therapy of cannabinoids and temozolomide against glioma.

Authors: Sofía Torres, Mar Lorente, Fátima Rodríguez-Fornés, Sonia Hernández-Tiedra, et al
Molecular Cancer Therapeutics, January 2011

Glioblastoma multiforme (GBM) is highly resistant to current anticancer treatments, which makes it crucial to find new therapeutic strategies aimed at improving the poor prognosis of patients suffering from this disease. Δ(9)-Tetrahydrocannabinol (THC), the major active ingred…

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.

Authors: José Alexandre S Crippa, Guilherme Nogueira Derenusson, Thiago Borduqui Ferrari, et al
Journal of Psychopharmacology, January 2011

Animal and human studies indicate that cannabidiol (CBD), a major constituent of cannabis, has anxiolytic properties. However, no study to date has investigated the effects of this compound on human pathological anxiety and its underlying brain mechanisms. The aim of the prese…

Endocannabinoid involvement in endometriosis.

Authors: Natalia Dmitrieva, Hiroshi Nagabukuro, David Resuehr, Guohua Zhang, Stacy McAllister, et al
Pain, December 2010

Endometriosis is a disease common in women that is defined by abnormal extrauteral growths of uterine endometrial tissue and associated with severe pain. Partly because how the abnormal growths become associated with pain is poorly understood, the pain is difficult to alleviat…

Use of dronabinol (delta-9-THC) in autism: A prospective single-case-study with an early infantile autistic child.

Authors: René Kurz, Kurt Blaas
Cannabinoids, 21 November 2010

Objective: To evaluate the effectiveness of dronabinol (delta-9-THC) as supplementary therapy in a child with autistic disorder. Methods: A child who met the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) criteria for a diagnosis of autistic disorder and who to…

Smoked cannabis for chronic neuropathic pain: a randomized controlled trial.

Authors: Mark A. Ware, Tongtong Wang, Stan Shapiro, Ann Robinson, Thierry Ducruet, Thao Huynh, et al
CMAJ, 5 October 2010

BACKGROUND: Chronic neuropathic pain affects 1%-2% of the adult population and is often refractory to standard pharmacologic treatment. Patients with chronic pain have reported using smoked cannabis to relieve pain, improve sleep and improve mood. METHODS: Adults with post-tra…

Cannabis use in palliative care – an examination of the evidence and the implications for nurses.

Authors: Anita J Green, Kay De‐Vries
Journal of Clinical Nursing, September 2010

AIM AND OBJECTIVE: Examine the pharmaceutical qualities of cannabis including a historical overview of cannabis use. Discuss the use of cannabis as a clinical intervention for people experiencing palliative care, including those with life-threatening chronic illness such as mu…

Do cannabinoids have a therapeutic role in transplantation?

Authors: Mitzi Nagarkatti, Sadiye Amcaoglu Rieder, Venkatesh L. Hegde, Shunsuke Kanada, et al
Trends in Pharmacological Sciences, August 2010

Cannabinoids have emerged as powerful drug candidates for the treatment of inflammatory and autoimmune diseases due to their immunosuppressive properties. Significant clinical and experimental data on the use of cannabinoids as anti-inflammatory agents exist in many autoimmune…